SM16 compound
an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model; structure in first source
Also Known As:
4-(5-(benzo(d)(1,3)dioxol-5-yl)-4-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)bicyclo(2.2.2)octane-1-carboxamide
Networked: 0
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results